Hui Martha Lok-Yung, Tan Loh Teng-Hern, Letchumanan Vengadesh, He Ya-Wen, Fang Chee-Mun, Chan Kok-Gan, Law Jodi Woan-Fei, Lee Learn-Han
Novel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia.
Clinical School Johor Bahru, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Johor Bahru 80100, Malaysia.
Antibiotics (Basel). 2021 Jun 8;10(6):682. doi: 10.3390/antibiotics10060682.
Actinobacteria constitute prolific sources of novel and vital bioactive metabolites for pharmaceutical utilization. In recent years, research has focused on exploring actinobacteria that thrive in extreme conditions to unearth their beneficial bioactive compounds for natural product drug discovery. Natural products have a significant role in resolving public health issues such as antibiotic resistance and cancer. The breakthrough of new technologies has overcome the difficulties in sampling and culturing extremophiles, leading to the outpouring of more studies on actinobacteria from extreme environments. This review focuses on the diversity and bioactive potentials/medically relevant biomolecules of extremophilic actinobacteria found from various unique and extreme niches. Actinobacteria possess an excellent capability to produce various enzymes and secondary metabolites to combat harsh conditions. In particular, a few strains have displayed substantial antibacterial activity against methicillin-resistant (MRSA), shedding light on the development of MRSA-sensitive antibiotics. Several strains exhibited other prominent bioactivities such as antifungal, anti-HIV, anticancer, and anti-inflammation. By providing an overview of the recently found extremophilic actinobacteria and their important metabolites, we hope to enhance the understanding of their potential for the medical world.
放线菌是用于药物利用的新型重要生物活性代谢物的丰富来源。近年来,研究集中在探索生长于极端条件下的放线菌,以挖掘其有益生物活性化合物用于天然产物药物发现。天然产物在解决诸如抗生素耐药性和癌症等公共卫生问题方面发挥着重要作用。新技术的突破克服了极端微生物采样和培养的困难,导致对来自极端环境的放线菌的研究大量涌现。本综述聚焦于从各种独特极端生态位中发现的嗜极端放线菌的多样性及其生物活性潜力/与医学相关的生物分子。放线菌具有产生各种酶和次生代谢物以对抗恶劣条件的卓越能力。特别是,一些菌株对耐甲氧西林金黄色葡萄球菌(MRSA)表现出显著的抗菌活性,为开发对MRSA敏感的抗生素提供了线索。若干菌株展现出其他突出的生物活性,如抗真菌、抗HIV、抗癌和抗炎活性。通过概述最近发现的嗜极端放线菌及其重要代谢物,我们希望增进对它们在医学领域潜力的理解。